Investors

Press Releases

 
Press Releases
  Date Title View
Jan 8, 2009
RESEARCH TRIANGLE PARK, N.C. – January 8, 2009 – Drug discovery company, SCYNEXIS, Inc., today announced top-line results from a Phase 1b randomized, double-blind, placebo-controlled study of its lead oral antiviral drug candidate, SCY-635, in adult patients with chronic hepatitis C (HCV) infection. Treatment with ...
Dec 11, 2008
RESEARCH TRIANGLE PARK, NC, USA, and GENEVA, SWITZERLAND (Dec. 11 , 2008) -SCYNEXIS, Inc. and Drugs for Neglected Diseases initiative (DNDi) announced today that they have extended their collaboration on vital drug discovery research and development of affordable and effective therapies for human African trypanosomiasis (also ...
Nov 3, 2008
RESEARCH TRIANGLE PARK, N.C. — November 3, 2008 — Drug discovery company SCYNEXIS, Inc. today announced that data from preclinical studies of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in poster sessions at the 59th Annual Meeting of the American Associat...
Jun 9, 2008
RESEARCH TRIANGLE PARK, N.C. — June 9, 2008 — Drug discovery company SCYNEXIS, Inc. is hosting a panel of world-class experts who will convene for a scientific review of the use of cyclophilin inhibitors in the treatment of human diseases. Cyclophilin inhibition is an exciting mechanism for targeting and inactivati...
Mar 27, 2008
Research Triangle Park, N.C., March 27, 2008 – SCYNEXIS, Inc. a premier drug discovery and development company, today announced the successful completion of a $13.5 million Series C-2 financing. The financing was led by Merial Limited, a joint venture between Merck & Co., Inc. and sanofi-aventis. SR One, GlaxoSmithKl...
FirstPrevious ...
13
= add release to Briefcase